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Abstract
Alzheimer’s Disease (AD), the most common form of de-
mentia, is a chronic neurodegenerative disease. The HECT 
domain and ankyrin repeat containing E3 ubiquitin protein 
ligase 1 (HACE1) gene is expressed in human brain and 
may play a role in the pathogenesis of neurodegenerative 
disorders. Till now, no previous study has reported the as-
sociation of the HACE1 gene with the risk and Age at Onset 
(AAO) of AD; while few studies have checked the propor-
tional hazards assumption in the survival analysis of AAO 
of AD using Cox proportional hazards model. In this study, 
we examined the associations of 14 Single Nucleotide Poly-
morphisms (SNPs) in the HACE1 gene with the risk and the 
AAO of AD using 791 AD patients and 782 controls. Multiple 
logistic regression model identified one SNP (rs9499937 
with p = 1.8 × 10-3) to be associated with the risk of AD. For 
survival analysis of AAO, both classic Cox regression model 
and Bayesian survival analysis using the Cox proportional 
hazards model were applied to examine the association of 
each SNP with the AAO. The Hazards Ratio (HR) with its 
95% Confidence Interval (CI) was estimated. Survival anal-
ysis using the classic Cox regression model showed that 4 
SNPs were significantly associated with the AAO (top SNP 
rs9499937 with HR = 1.33, 95% CI = 1.13-1.57, p = 5.0 × 
10-4). Bayesian Cox regression model showed similar but a
slightly stronger associations (top SNP rs9499937 with HR 
= 1.34, 95% CI = 1.11-1.55) compared with the classic Cox 
regression model. Using an independent family-based sam-
ple, one SNP rs9486018 was associated with the risk of 
AD (p = 0.0323) and the T-T-G haplotype from rs9786015, 
rs9486018 and rs4079063 showed associations with both 
the risk and AAO of AD (p = 2.27 × 10-3 and 0.0487, respec-
tively). The findings of this study provide first evidence that 
several genetic variants in the HACE1 gene were associat-
ed with the risk and AAO of AD.
Keywords
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Alzheimer’s Disease (AD) is a chronic neurodegener-
ative disease [1]. It is estimated that, in 2010, about 4.7 
million people in the United States (US) aged 65 years or 
older live with AD, and this number is projected to rise 
to 13.8 million, a nearly three-fold increase, by 2050 [2]. 
Weuve et al. [3] estimated the number of adults (aged 
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has been used to detect genetic associations with the 
AAO of AD [27-29], the proportional hazards assump-
tion may be violated and they might not be carefully 
checked. Bayesian methods have been widely used re-
cently in genetic association studies and provide alter-
native ways to traditional statistical methods [30-32]. In 
this study, we explored the association of HACE1 with 
the AAO of AD by using a Bayesian proportional hazards 
model in a population-based sample and then a fami-
ly-based sample for replication.
Subjects and Methods
Study population
791 patients with AD and 782 controls with complete 
genotype and phenotype information in a Canadian 
sample were selected from the Multi-Site Collaborative 
Study for Genotype-Phenotype Associations in Alzhei-
mer's disease and the longitudinal follow-up of Geno-
type-Phenotype Associations in Alzheimer's disease and 
the Neuroimaging component of Genotype-Phenotype 
Associations in Alzheimer's disease-Study Accession: 
phs000219.v1.p1. Covariates include sex and age. The 
details about these subjects were described in previous 
studies [27,33]. Genotyping was conducted using the 
Affymetrix technique. The genotypes of 14 SNPs within 
the HACE1 gene were available in this data.
A family-based study (1266 AD cases and their rel-
atives, 1070 individuals with the AAO values) were 
available from the National Institute on Aging - Late 
Onset Alzheimer's Disease (NIA-LOAD) Family Study: 
Genome-Wide Association Study for Susceptibility Loci 
- Study Accession: phs000168.v1.p1. Genotyping by the 
Center for Inherited Disease Research (CIDR) was per-
formed using the Illumina Infinium II assay protocol. 
The details about the sample of subjects were described 
elsewhere [34]. There are 28 SNPs within the HACE1 
gene in this family-based sample.
Statistical analysis
Descriptive statistics and genotype quality control: 
Descriptive statistics were used to characterize partici-
pants’ sex, age and the AAO of AD stratified by AD case 
and control status [29,35]. Hardy-Weinberg Equilibri-
um (HWE) was tested for all SNPs using the controls by 
HAPLOVIEW software [36]. Then, Minor Allele Frequen-
cy (MAF) was determined for each SNP. Pair wise Link-
age Disequilibrium (LD) statistics (r2) among SNPs were 
assessed using the European sample from the HapMap 
dataset (http://hapmap.ncbi.nlm.nih.gov/) and the 
founders in the family study.
Multiple logistic and linear regression models in 
PLINK software: Multiple logistic regression analysis of 
each SNP with the risk of AD as a binary outcome, ad-
justed for sex and age, was performed using PLINK [37]; 
while the asymptotic p-values were obtained and the 
Odds Ratio (OR) and 95% Confident Interval (CI) were 
≥ 65 years) with AD in each US state and the District 
of Columbia (DC) and found that the number of older 
adults (aged ≥ 65 years) with AD in the US ranged from 
5.1 (Alaska) to 530 million (California) in 2010; while in 
2010, older adults with AD dementia comprised a medi-
an of 1.6% of a given state’s total population; whereas 
by 2025, throughout the US, this proportion will keep 
increasing by nearly one-third on average [3]. The prev-
alence was estimated to be about 3.12% in 2012 for old-
er adults (≥ 60 years) in the US using the Nationwide In-
patient Sample (NIS) 2002-2012 [4]. A meta-analysis es-
timated the prevalence for the combined population of 
African-Americans and Caucasians aged 65-90 in 2013 
was 5.7% in the US; the prevalence for African-Ameri-
cans aged 65-90 years was 8.6%, compared to 5.5% for 
Caucasians [5]. Globally, 26.6 million people (0.40% of 
the world population) suffered from AD in 2006 and it 
was predicted to affect 1 in 85 people by 2050 [6]. A 
recent meta-analysis showed that the prevalence of AD 
in Europe was 5.05% for adult (aged ≥ 50 years) (3.31% 
for males and 7.13% females) [7]. Increasing evidence 
suggests that autophagy may play a central role in AD 
[8,9]. The genetic heritability of AD ranges from 49% to 
79% based on reviews of twin and family studies [10]. In 
addition to the risk, the Age at Onset (AAO) of AD has a 
genetic component with heritability about 42% [11,12].
The HECT domain and ankyrin repeat containing E3 
ubiquitin protein ligase 1 (HACE1) gene (also known as 
KIAA1320) is located at 6q16.3 [13-15]. The HACE1 is 
expressed in brain, heart, lung, kidney, testis, and ova-
ry [13,15]. Several studies have implicated that HACE1 
is a candidate chromosome 6q21 tumor suppressor 
gene involved in multiple cancers [16-18]. Recently, it 
has been reported that HACE1 gene may play a role in 
neurodegeneration [19] and autophagy pathway [20]; 
while HACE1 mutations are involved in an autosomal 
recessive neurodevelopmental disorder [21], and gluta-
mine addiction [22]. A Genome-Wide Association Study 
(GWAS) identified five Single-Nucleotide Polymor-
phisms (SNPs) (rs17065302, rs11759010, rs6927608, 
rs4946645 and rs4245525) within the HACE1 gene 
associated with equol-producing phenotype such as 
blood pressure, which may implicate HACE1 in intesti-
nal immune responses [23]. Another GWAS identified 5 
SNPs (rs4336470. rs9404576, rs4079063, rs24996663, 
and rs2499667) in HACE1 associated with neuroblas-
toma susceptibility [24]; while in a replication study, 
rs4336470 showed moderate association (p < 0.05) with 
risk of neuroblastoma [25]. More recently, it has been 
reported that the five above SNPs in the HACE1 gene 
may have a weak combined effect (p = 0.065) on neu-
roblastoma risk in Southern Chinese children [26]. Thus 
we hypothesized that HACE1 genetic variants may be in 
association with AD development.
To our best knowledge, no study has focused on the 
association of the HACE1 gene with the risk and AAO 
of AD. Even though the Cox proportional hazards model 
ISSN: 2469-5831DOI: 10.23937/2469-5831/1510014
Ke-Sheng et al. Int J Clin Biostat Biom 2017, 3:014 • Page 3 of 11 •
puted for each of the parameters. Trace plots, posterior 
density plots, and autocorrelation function plots were 
also provided [32]. For Bayesian survival analysis of the 
AAO of AD, the normal prior was chosen for the coeffi-
cients and the Deviance Information Criteria (DIC) was 
available instead of AIC. DIC is intended as a general-
ization of AIC [46]. A measure of effective numbers of 
parameters is defined as pD in (4), where pD is the poste-
rior mean deviance minus the deviance measured at the 
posterior mean of the parameters.
( ){ } ( ){ }| ˆ 2  | 2  Dp E ln p x ln p xθ θ = − +                               (4)
Then DIC is defined analagously to AIC as in (5). Mo-
dels with smaller DIC are better supported by the data.
( ){ } DˆDIC = -2ln  p x pθ +                                          (5)
The PHREG procedure in SAS was used to fit the Cox 
model. Multiple Cox regression model analysis, adjusted 
for sex and age, was conducted to examine association 
of each SNP with the AAO of AD. Descriptive statistics 
and Cox regression analysis were performed with SAS 
v.9.4 (SAS Institute, Cary, NC, USA).
Family-based study: A family-based association 
analysis for AD was performed using PBAT version 3.6.7 
[47]. For the risk of AD, the Family-Based Association 
Test using Generalized Estimating Equations (FBAT-GEE) 
was used [48]; while for the AAO, FBAT-Wilcoxon sta-
tistics were employed [49]. The AAO values for healthy 
siblings were censored and age at entry into the study 
was used. Haplotype analysis was conducted in 2 or 
3-SNP sliding window.
Results
Descriptive statistics and genotype quality control
The demographic characteristics of the subjects are 
detailed in Table 1. The mean AAO for cases was 76.4 
and 72.3 years, respectively, in the NIA and Canadian 
samples, respectively. All 14 SNPs had MAF > 5% and 
were in HWE in the controls (p > 0.05); while 1 of 28 
SNPs with HWE < 0.10-4 in the family sample was re-
moved for further analysis.
Multiple linear and logistic regression analyses using 
PLINK
We found that one SNP was associated with the risk 
of AD (rs9499937 with p = 1.8 × 10-3) and four SNPs were 
estimated. The parallel procedure was performed for 
the multiple linear regression analysis of each SNP with 
the AAO of AD as a continuous outcome. Bonferroni 
correction (α = 0.05/14 = 3.57 × 10-3) was used to deal 
with the multiple comparison issue [38].
Bayesian Cox proportional hazards model in PROC 
PHREG: The Cox proportional hazards model (1) or Cox 
regression model [39] is widely used in the analysis of 
time-to-event data [40-42].
( ) ( )0 1 2 3( | )  kh t x h t exp SNP Sex Ageβ β β= + +                (1)
where ( / )h t x  is the hazard at time t for a subject 
(AAO for this study), ( )0h t  is the baseline hazard func-
tion. The Hazard Ratio (HR) is defined as the ratio of the 
predicated hazard function under two different values 
of a predictor variable. The PHREG procedure in SAS fits 
the Cox model by maximizing the partial likelihood func-
tion. Both the graphical and numerical methods [43] 
were used to check the proportional hazards assump-
tion in the ASSESS option of PROC PHREG. The ASSESS 
option plots the cumulative score residuals against time 
for each independent variable; while the RESAMPLE op-
tion computes the p-value of a Kolmogorov-type supre-
mum test based on a sample of 1,000 simulated residual 
patterns. A significant p-value indicates a poor fit.
The Akaike Information Criterion (AIC) (2) was used 
as a measure of better fit among candidate models 
[44,45].
{ }ˆ( | )C  2 2AI ln p x kθ− +=                                    (2)
where x is the random variable,  is the maximum 
likelihood estimate, and k is the number of parameters. 
A smaller AIC generally indicates a better fit.
Bayesian statistics is an extension of Bayes theorem, 
which can be written as (3)





θ =                                           (3)
where θ is the parameter of interest, Y is the ob-
served evidence, P(Y) is the marginal probability, P(Y|θ) 
is the likelihood function, P(θ) is the prior, and P(θ|Y) 
is the posterior probability [32]. Bayesian Cox regres-
sion can be requested by using the BAYES statement in 
the PHREG procedure. Summary statistics (Mean, Stan-
dard Deviation, the Highest Posterior Density (HPD) and 
Credible Intervals, and Correlation Matrix) were com-
Table 1: Descriptive characteristics of cases and controls.
Variable Family study (NIA sample) Case-control study (Canadian sample)
Patients Controls Patients Controls
Sample size (n) 1266 1279 791 782
Mean of age at onset (years ± SD) 76.4 (± 6.7) - 72.3 (± 8.5) -
Median of age at onset (years) 77 - 73 -
Range of age at onset (years) 50-98 - 40-97 -
Mean age at entry (years ± SD) - 75.5 (± 8.1) 77.6 (± 8.6) 73.4 (± 7.9)
Median age at entry (years) - 75 79 79
Range of age at entry (years) - 42 - 103 43 - 100 48 - 94
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premum test results based on 1,000 simulations for all 
the covariates were not significant (p > 0.05), suggesting 
the proportional hazards assumption was valid for all 
the variables in the Canadian sample.
Classic Bayesian Cox proportional hazards model us-
ing PROC PHREG
The classic Cox model showed that four SNPs were 
associated with the AAO of AD (the CT genotype of the 
top SNP rs9499937 with HR = 1.33, 95% CI = 1.13-1.57, 
p = 5.0 × 10-4). The HRs based on the Bayesian survival 
analyses revealed similar but a slightly stronger asso-
ciations compared with the non-Bayesian analyses re-
sults (Table 3). The DIC for the four SNPs were similar 
to those of AIC. The trace plot, posterior density plot, 
and autocorrelation function plot based on Bayesian 
associated with the AAO of AD (rs7746856, rs6941988, 
rs9499937 and rs7770002 with p = 3.09 × 10-2, 3.88 × 
10-3, 7.39 × 10-4, and 3.14 × 10-2, respectively) (Table 2). 
Interestingly, the same SNP rs9499937 showed associa-
tions with both the risk and AAO of AD and the results 
remained significant after Bonferroni correction (p < 
3.57 × 10-3).
Supremum test for proportional hazards assumption
Figure 1 and Figure 2 display the observed standard-
ized score process with 20 simulated realizations from 
the null distribution for rs9499937 CC and CT geno-
types, respectively. The plots showed that the observed 
process was atypical compared to the simulated reali-
zations and revealed proportional hazards for the two 
genotypes compared with TT. The Kolmogorov-type su-
Table 2: SNPs associated with the risk and/or age at onset of AD (p < 0.05).
SNP Position Allelea MAFb HWEc OR-ADd p-ADe β-AAOf p-AAOg
rs7746856 105253053 A 0.47 0.787 0.92 (0.79 - 1.06) 0.246 -0.367 (-0.70, -0.034) 0.0309
rs6941988 105253349 C 0.47 0.84 0.92 (0.79 - 1.06) 0.239 -0.351 (-0.68, -0.019) 0.00388
rs9499937 105273953 T 0.19 0.649 0.73 (0.60 - 0.89) 1.80 × 10-3 -0.79 (-1.25, -0.34) 7.39 × 10-4
rs7770002 105280138 A 0.47 0.96 0.92 (0.80 - 1.07) 0.268 -0.366 (-0.70, -0.033) 0.0314
aMinor allele; bMinor allele frequency; cHardy-Weinberg equilibrium test p-value; dOdds ratio based on logistic regression; ep-value 
based on logistic regression; fRegression coefficient for Age at Onset (AAO) based on multiple linear regression; gp-value based 
on linear regression.
Checking Proportional Hazards Assumption for rs9499937C_C
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Figure 1: Explore plot for checking proportional hazards assumption for rs9499937C_C gentoype compared with rs9499937T_T 
genotype.
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type from rs9786015 and rs9486018 and the T-G hap-
lotype from rs9486018 and rs4079063 showed signifi-
cant association with the risk (p = 1.56 × 10-3 and 4.46 
× 10-3, respectively) (Table 4). Using the FBAT-Wilcoxon 
test, the C-C haplotype from rs6937026 and rs6946640 
revealed mostly significant associations with the AAO 
(p = 0.0223). The C-A-G and C-C-A haplotype from 
rs6437026, rs4946640 and rs6910034 showed associa-
tions with the AAO (p = 0.0274 and 0.0225, respective-
ly). The T-T-G haplotype from rs9786015, rs9486018 
and rs4079063 showed associations with both the risk 
(p = 2.27 × 10-3) and the AAO (p = 0.0487).
analysis (Figure 3) indicated that the Markov chain had 
stabilized with good mixing for rs9499937. The poste-
rior density plot, which estimates the posterior mar-
ginal distributions for the four regression coefficients, 
showed a smooth and unimodal shape for the posterior 
marginal distribution (Figure 4).
Family-based association analysis
We observed one SNP associated with the risk of AD 
(rs9486018 with p = 0.0323) by using FBAT-GEE analy-
sis in the family-based study. The T-A haplotype from 
rs6937432 and rs6940552 revealed mostly significant 
associations with the risk (p = 9.7 × 10-4). The T-T haplo-
Checking Proportional Hazards Assumption for rs9499937C_T
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Figure 2: Explore plot for checking proportional hazards assumption for rs9499937C_T compared with rs9499937T_T.
SNP GTa HRb pc AICd HRe HPDf DICg
rs7746856 C-C 7622.19 7622.21
A-A 1.28 (1.04 - 1.57) 0.0208 1.28 1.02 - 1.56
A-G 1.02 (0.87 - 1.20) 0.82 1.02 0.86 - 1.19
rs6941988 T-T 7622.24 7622.32
C-C 1.27 (1.03 - 1.56) 0.026 1.27 1.02 - 1.54
C-T 1.01 (0.85 - 1.18) 0.959 1.01 0.85 - 1.18
rs9499937 C-C 7616.16 7616.17
C-T 1.33 (1.13 - 1.57) 5.0 × 10-4 1.34 1.11 - 1.55
T-T 1.35 (0.80 - 2.27) 0.266 1.35 0.68 - 2.06
rs7770002 A-G 7622.37 7622.34
A-C 1.27 (1.03 - 1.57) 0.0239 1.28 1.02 - 1.55
C-C 1.01 (0.86 - 1.20) 0.864 1.02 0.85 - 1.19
aTested genotype comparing with the reference; bHazards Ratio (HR) for the tested genotype based on classic Cox regression 
analysis using PROC PHREG; cp-value for the tested genotype based on classic Cox regression analysis; dAkaike Information 
Criterion (AIC) value based on classic Cox regression analysis; eHR for the tested genotype based on Bayesian Cox regression 
analysis; fLower and upper 95% Highest Posterior Density (HPD) of HR based on Bayesian Cox regression analysis; gDeviance 
Information Criteria (DIC) value based on Bayesian Cox regression analysis.
Table 3: SNPs associated with the age at onset of AD using PROC PHREG (p < 0.05).
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ciated SNP rs9499937 (r2 = 0.27). Furthermore, there was 
strong LD observed between rs2499663 and three AAO 
associated SNPs (rs7746856, rs6941988 and rs7770002 
with r2 = 0.81, 0.81 and 0.93, respectively). Using the 
founders in the family study, LD structure based on (r2) 
was constructed for all 28 SNPs (Figure 6). The two neu-
roblastoma associated SNPs (rs4336470 and rs9404576) 
[24,25] had moderate LD with SNPs (such as rs6910034, 
rs9404573, rs9499934, rs696937432, rs9486015, and 
rs4079063) which built AD and AAO associated haplo-
type; while another neuroblastoma associated SNPs 
rs2499663 [24,25] had moderate or strong LD with SNPs 
involved in AD and AAO associated haplotype.
The linkage disequilibrium structure of the HACE1 
gene
Using the HapMap data, we identified one haplotype 
block including the four SNPs associated AD and/or AAO 
in the case-control study. Figure 5 shows the LD struc-
ture based on LD statistics (r2). Based on the rough rule of 
thumb, values of r2 > 1/3 might indicate sufficiently strong 
LD that can be used for a fine mapping [50]. The neuro-
blastoma associated rs4336470 [24,25] had moderate or 
strong LD with three AAO associated SNPs (rs7746856, 
rs6941988 and rs7770002 with r2 = 0.6, 0.6 and 0.71, re-
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Figure 3: Trace plot, autocorrelation function plot, and posterior density plot for rs9499937.
Table 4: Haplotype analysis of the risk and age at onset of AD in the family sample.
 SNPs  Haplotypea Frequencyb Fam#c p-valued
Risk of AD
rs9499927 rs9404573  C-C 0.01 37 0.00144
rs9404573 rs9499934  C-T 0.02 41 0.00355
rs6937432 rs6940552  T-A 0.01 37 0.00097
rs1378720 rs13198196  C-T 0.02 60 0.0147
rs9486015 rs9486018  T-T 0.06 101 0.00156
rs9486018 rs4079063  T-G 0.07 120 0.00446
rs9486015 rs9486018 rs4079063 T-T-G 0.04 54 0.00227
Age at onset of AD
rs6937026 rs4946640  C-C 0.23 166 0.0223
rs6937026 rs4946640 rs6910034 C-A-G 0.51 156 0.0274
   C-C-A 0.16 100 0.0225
rs9486015 rs9486018 rs4079063 T-T-A 0.01 22 0.0719
   T-T-G 0.04 46 0.0487
aHaplotype inferred from 2 or 3 SNPs; bHaplotype frequency; cFAM# refers to the number of informative families using an additive model; 
dp-value for the haplotype based on FBAT-GEE analysis for the risk or based on FBAT-Wilcoxon analysis for the age at onset.
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ly stronger associations with the AAO of AD. Using an 
independent family-based sample, one SNP rs9486018 
was associated with the risk of AD while haplotype anal-
yses further revealed the associations with the risk and 
AAO of AD. The findings of this study provide the first 
evidence that several genetic variants in the HACE1 
gene influenced the risk and the AAO of AD.
A previous study suggested that rs9391227 in the 
Discussion
In the present study we explored the association 
of 14 HACE1 SNPs with the risk and AAO of AD using 
a case-control study and identified one SNP associat-
ed with AD and four SNPs with the AAO of AD using 
PLINK software. Interestingly, the same SNP rs9499937 
showed associations with both the risk and AAO of AD. 
Bayesian Cox regressions revealed similar but a slight-
Posterior Density Plots
rs9499937C_T
-1.0            -0.5            0.0              0.5             1.0
rs9499937T_T
Sex1 age
0.0                   0.2                   0.4                   0.6
-0.2                     0.0                     0.2                     0.4 -0.42        -0.40        -0.38        -0.36        -0.34        -0.32
Figure 4: The posterior density plots for the 4 regression coefficients.
Figure 5: Linkage disequilibrium structure (r2) within the HACE1 gene using the HapMap data (Dark area shows r2 = 1).
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Figure 6: Linkage disequilibrium structure (r2) within the HACE1 gene of 28 SNPs in the family sample (Dark area shows r2 = 1).
was found to be associated with the risk of AD; while 
the T-T-A haplotype inferred from the rs9486015, 
rs9486018 and rs4079063 was found to be associated 
with the AAO of AD in the family-based study (Table 
4). Furthermore, four neuroblastoma associated SNPs 
(rs4336470, rs9404576, rs4079063 and rs2499663) [24-
26] had moderate to strong LDs with SNPs which built 
AD and AAO associated haplotypes (Figure 6). In addi-
tion, recently, it has been reported that HACE1 may play 
a role in neurodevelopment and addiction [19,21,22]. 
Taken together, the above findings may suggest that 
HACE1 gene may be involved in the pathogenesis of AD, 
cancers and blood pressure; however, the mechanism 
warrants further studies.
Several strengths of this study are worthy of noting. 
The present study provides the first evidence of several 
genetic variants within the HACE1 gene associated with 
the risk and the AAO of AD using a case-control sample 
and a family-based sample for replication. Furthermore, 
we checked the proportional hazards assumption using 
both the graphical and numerical methods for the Cox 
proportional hazards model and found that the propor-
tional hazards assumption was valid for the AAO of AD 
data in the Canadian sample. In addition, we conducted 
Bayesian survival analysis of genetic variants with the 
AAO of AD. Bayesian method may provide an alterna-
tive approach to assessing and verifying associations 
that alleviates the limitations of p-values at the cost 
of some additional modeling and it has recently made 
great inroads in genetic association studies [30]. Like 
other research studies, some limitations also exist in this 
study. First, due to different genotyping platforms, only 
HACE1 gene was associated with celiac disease involved 
in the immune system and antigen presentation [51]; 
while another study revealed that five SNPs (rs17065302, 
rs11759010, rs6927608, rs4946645 and rs4245525) 
within HACE1 gene associated with equol-producing 
phenotype such as blood pressure [23] which may impli-
cate HACE1 in immune responses. However, rs9391227 
[51] was not available in both the case-control and 
family-based samples; while equol-producing pheno-
type associated five SNPs [23] were not associated with 
the risk or the AAO of AD in the case-control study and 
rs6927608 was not associated with the risk and AAO of 
AD in both samples. However, rs9391227 had strong LD 
with three AAO associated SNPs (rs7746856, rs6941988 
and rs7770002 with r2 = 1.0, 1.0 and 0.87, respectively) 
in the case-control study (Figure 5); whereas rs6927608 
had weak LD with other SNPs (Figure 5 and Figure 6). 
Previous studies have shown that AD is a chronic neuro-
degenerative disease while autophagy, immune and in-
flammatory processes are involved in the pathogenesis 
of AD [1,8,9,52-56].
Previous epidemiology studies have suggested co-
morbidity of AD with certain cancers [57-59]; whereas 
there may be an inverse link between cancer and AD 
[59-61]. Recently, a meta-analysis of nine studies sup-
ports an association between AD and decreased cancer 
risk [62]. However, the mechanism still remains un-
clear [60]. Several SNPs (such as rs4336470, rs9404576, 
rs4079063, rs24996663, and rs2499667) in the HACE1 
have been found to be associated with neuroblasto-
ma susceptibility [24-26]. In the present study, the T-G 
haplotype inferred from the rs9486018 and rs4079063 
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